[Development of vaccine for enterohemorrhagic Escherichia coli infection].
Efforts on the development of vaccines against enterohemorrhagic Escherichia coli (EHEC) infection has been described in this review. Two kinds of vaccines were developed and these have been targeted for in humans and cattle. One vaccine candidate is toxoid, which uses an inactive form of Shiga toxin(Stx). A part of B subunit, each B or A subunit or one or two amino acid mutated holotoxin were developed as a toxoid vaccine candidate. The other candidate was bacterial surface antigen such as a live attenuated EHEC and hybrid between non-toxic LPS and toxoid. A live attenuated vaccine against EHEC O26: H11, O157: H7, O139: H1 were developed. Further a live attenuated vaccine candidate of Vibrio cholerae O1 expressing Stx1-B, Shigella flexneri expressing S. dysenteriae O-antigen and Stx1-B, or Salmonella Typhimurium expressing O111 antigen were developed. Hybrid type vaccine candidates were also developed with O111 LPS and tetanus toxoid, O157 LPS and exotoxin, and O157 LPS and Stx1-B.
Yamasaki
Shinji
S
Department of Veterinary Sciences, Graduate School of Agriculture and Biological Sciences, Osaka Prefecture University.
D000818:Animals; D001428:Bacterial Vaccines; D002417:Cattle; D004927:Escherichia coli Infections / Q000517:prevention & control*; D019453:Escherichia coli O157; D006801:Humans; D022621:Shiga Toxin; D014613:Vaccines, Attenuated
D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D022621:Shiga Toxin